Standard Biotools Stock Buy Hold or Sell Recommendation
| LAB Stock | USD 1.21 0.05 4.31% |
Considering the 90-day investment horizon and your above-average risk tolerance, our recommendation regarding Standard Biotools is 'Strong Sell'. Macroaxis provides Standard Biotools buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding LAB positions.
Check out Standard Biotools Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide. In addition, we conduct extensive research on individual companies such as Standard and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
Standard |
Execute Standard Biotools Buy or Sell Advice
The Standard recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Standard Biotools. Macroaxis does not own or have any residual interests in Standard Biotools or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Standard Biotools' advice using the current market data and latest reported fundamentals.
Time Horizon
3 Months |
Risk Tolerance
I am an educated risk taker |
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves completely opposite to the market | Details | |
Investor Sentiment | Excited | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Standard Biotools Trading Alerts and Improvement Suggestions
| Standard Biotools generated a negative expected return over the last 90 days | |
| Standard Biotools has high historical volatility and very poor performance | |
| Standard Biotools may become a speculative penny stock | |
| The company reported the last year's revenue of 174.43 M. Reported Net Loss for the year was (138.88 M) with profit before taxes, overhead, and interest of 84.26 M. | |
| Standard Biotools has about 81.31 M in cash with (143.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 73.0% of the company shares are owned by institutional investors | |
| Latest headline from prnewswire.com: ANY LAB TEST NOW Enters Entrepreneur Magazines Prestigious Franchise 500 Hall of Fame |
Standard Biotools Returns Distribution Density
The distribution of Standard Biotools' historical returns is an attempt to chart the uncertainty of Standard Biotools' future price movements. The chart of the probability distribution of Standard Biotools daily returns describes the distribution of returns around its average expected value. We use Standard Biotools price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Standard Biotools returns is essential to provide solid investment advice for Standard Biotools.
| Mean Return | -0.52 |
| Value At Risk | -9.29 |
| Potential Upside | 6.21 |
| Standard Deviation | 5.98 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Standard Biotools historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Standard Biotools Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change To Inventory | (8.6M) | (4.8M) | (8.5M) | (4.9M) | (9.9M) | (9.4M) | |
| Change In Cash | 45.8M | (40.1M) | 52.9M | (29.8M) | 116.3M | 122.1M | |
| Free Cash Flow | (28.1M) | (57.3M) | (93.2M) | (46.1M) | (151.8M) | (144.2M) | |
| Depreciation | 15.9M | 15.6M | 15.0M | 15.2M | 4.3M | 4.1M | |
| Other Non Cash Items | 4.6M | 3.4M | 86.3M | 1.3M | (40.6M) | (38.6M) | |
| Capital Expenditures | 12.7M | 13.3M | 3.8M | 2.8M | 8.4M | 4.9M | |
| Net Income | (53.0M) | (59.2M) | (190.1M) | (74.7M) | (138.9M) | (131.9M) | |
| End Period Cash Flow | 69.5M | 29.5M | 82.3M | 52.5M | 168.8M | 177.3M | |
| Investments | 36.8M | (11.9M) | (88.1M) | 73.6M | 363.2M | 381.3M | |
| Change To Netincome | 25.4M | 16.7M | 18.4M | 30.7M | 35.3M | 22.8M |
Standard Biotools Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Standard Biotools or Life Sciences Tools & Services sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Standard Biotools' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Standard stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.41 | |
β | Beta against Dow Jones | 1.76 | |
σ | Overall volatility | 5.85 | |
Ir | Information ratio | -0.08 |
Standard Biotools Volatility Alert
Standard Biotools exhibits very low volatility with skewness of 1.39 and kurtosis of 5.65. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Standard Biotools' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Standard Biotools' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Standard Biotools Fundamentals Vs Peers
Comparing Standard Biotools' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Standard Biotools' direct or indirect competition across all of the common fundamentals between Standard Biotools and the related equities. This way, we can detect undervalued stocks with similar characteristics as Standard Biotools or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Standard Biotools' fundamental indicators could also be used in its relative valuation, which is a method of valuing Standard Biotools by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Standard Biotools to competition |
| Fundamentals | Standard Biotools | Peer Average |
| Return On Equity | -0.44 | -0.31 |
| Return On Asset | -0.18 | -0.14 |
| Profit Margin | (0.80) % | (1.27) % |
| Operating Margin | (0.29) % | (5.51) % |
| Current Valuation | 198.7 M | 16.62 B |
| Shares Outstanding | 378.99 M | 571.82 M |
| Shares Owned By Insiders | 1.85 % | 10.09 % |
| Shares Owned By Institutions | 73.10 % | 39.21 % |
| Number Of Shares Shorted | 13.5 M | 4.71 M |
| Price To Earning | (2.52) X | 28.72 X |
| Price To Book | 0.97 X | 9.51 X |
| Price To Sales | 2.63 X | 11.42 X |
| Revenue | 174.43 M | 9.43 B |
| Gross Profit | 84.26 M | 27.38 B |
| EBITDA | (118.14 M) | 3.9 B |
| Net Income | (138.88 M) | 570.98 M |
| Cash And Equivalents | 81.31 M | 2.7 B |
| Cash Per Share | 2.68 X | 5.01 X |
| Total Debt | 33 M | 5.32 B |
| Debt To Equity | 0.38 % | 48.70 % |
| Current Ratio | 5.87 X | 2.16 X |
| Book Value Per Share | 1.23 X | 1.93 K |
| Cash Flow From Operations | (143.45 M) | 971.22 M |
| Short Ratio | 6.28 X | 4.00 X |
| Earnings Per Share | (0.52) X | 3.12 X |
| Price To Earnings To Growth | 0.31 X | 4.89 X |
| Target Price | 2.38 | |
| Number Of Employees | 814 | 18.84 K |
| Beta | 1.62 | -0.15 |
| Market Capitalization | 458.57 M | 19.03 B |
| Total Asset | 612.34 M | 29.47 B |
| Retained Earnings | (1.19 B) | 9.33 B |
| Working Capital | 309.99 M | 1.48 B |
Note: Disposition of 31031 shares by Michael Egholm of Standard Biotools at 1. subject to Rule 16b-3 [view details]
Standard Biotools Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Standard . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Standard Biotools Buy or Sell Advice
When is the right time to buy or sell Standard Biotools? Buying financial instruments such as Standard Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Standard Biotools in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Absolute Returns ETFs Thematic Idea Now
Absolute Returns ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Absolute Returns ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Absolute Returns ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Standard Biotools Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Standard Biotools. If investors know Standard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Standard Biotools listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.52) | Revenue Per Share | Quarterly Revenue Growth (0.14) | Return On Assets | Return On Equity |
The market value of Standard Biotools is measured differently than its book value, which is the value of Standard that is recorded on the company's balance sheet. Investors also form their own opinion of Standard Biotools' value that differs from its market value or its book value, called intrinsic value, which is Standard Biotools' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Standard Biotools' market value can be influenced by many factors that don't directly affect Standard Biotools' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Standard Biotools' value and its price as these two are different measures arrived at by different means. Investors typically determine if Standard Biotools is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Standard Biotools' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.